Aspen Aerogels (ASPN) Cash & Equivalents (2013 - 2026)

Aspen Aerogels (ASPN) has 14 years of Cash & Equivalents data on file, last reported at $173.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 9.43% year-over-year to $173.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.9 million (down 9.43% YoY) and the FY2025 annual result came in at $156.9 million, down 28.99% from the prior year.
• Cash & Equivalents advanced to $173.9 million in Q1 2026, from $156.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $281.3 million in Q4 2022 to a low of $91.4 million in Q2 2024.
• A 5-year average of $158.6 million and a median of $156.9 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 1091.71% — and 2024, when it plunged 51.08%.
• Tracing ASPN's Cash & Equivalents over 5 years: stood at $281.3 million in 2022, then plunged by 50.34% to $139.7 million in 2023, then soared by 58.09% to $220.9 million in 2024, then dropped by 28.99% to $156.9 million in 2025, then gained by 10.87% to $173.9 million in 2026.
• The last three Cash & Equivalents figures came in at $173.9 million (Q1 2026), $156.9 million (Q4 2025), and $150.7 million (Q3 2025), per Business Quant data.